$67.69
0.25%
Nasdaq, Oct 31, 09:14 pm CET
ISIN
NL0010696654
Symbol
QURE

uniQure N.V. Stock price

$67.69
+9.32 15.97% 1M
+52.93 358.60% 6M
+50.03 283.30% YTD
+61.97 1,083.39% 1Y
+49.07 263.53% 3Y
+26.82 65.62% 5Y
+48.91 260.44% 10Y
+53.08 363.31% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
-0.17 0.25%
ISIN
NL0010696654
Symbol
QURE
Industry

Key metrics

Basic
Market capitalization
$4.2b
Enterprise Value
$4.3b
Net debt
$130.1m
Cash
$377.0m
Shares outstanding
54.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
290.8 | 227.0
EV/Sales
299.9 | 234.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-1.2%
Return on Equity
3,547.9%
ROCE
-30.6%
ROIC
-84.6%
Debt/Equity
-126.8
Financials (TTM | estimate)
Revenue
$14.3m | $18.4m
EBITDA
$-150.8m | $-155.0m
EBIT
$-166.3m | $-182.5m
Net Income
$-199.0m | $-189.7m
Free Cash Flow
$-174.2m
Growth (TTM | estimate)
Revenue
-48.3% | -32.3%
EBITDA
34.1% | 5.8%
EBIT
30.9% | -3.0%
Net Income
30.1% | 20.8%
Free Cash Flow
-57.5%
Margin (TTM | estimate)
Gross
82.6%
EBITDA
-1,051.8% | -843.7%
EBIT
-1,159.9%
Net
-1,388.0% | -1,032.7%
Free Cash Flow
-1,215.3%
More
EPS
$-3.6
FCF per Share
$-3.2
Short interest
12.4%
Employees
209
Rev per Employee
$130.0k
Show more

Is uniQure N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

uniQure N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a uniQure N.V. forecast:

18x Buy
90%
2x Hold
10%

Analyst Opinions

20 Analysts have issued a uniQure N.V. forecast:

Buy
90%
Hold
10%

Financial data from uniQure N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
14 14
48% 48%
100%
- Direct Costs 2.49 2.49
91% 91%
17%
12 12
903% 903%
83%
- Selling and Administrative Expenses 46 46
29% 29%
324%
- Research and Development Expense 135 135
22% 22%
940%
-151 -151
34% 34%
-1,052%
- Depreciation and Amortization 16 16
28% 28%
108%
EBIT (Operating Income) EBIT -166 -166
31% 31%
-1,160%
Net Profit -199 -199
30% 30%
-1,388%

In millions USD.

Don't miss a Thing! We will send you all news about uniQure N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

uniQure N.V. Stock News

Negative
Reuters
28 minutes ago
UniQure , said on Monday its experimental gene therapy for Huntington's disease does not have adequate clinical data to support its marketing application, according to the U.S. Food and Drug Administration.
Neutral
GlobeNewsWire
42 minutes ago
LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gen...
Positive
Seeking Alpha
6 days ago
uniQure (QURE) is upgraded to Buy following strong 36-month high-dose AMT-130 data for Huntington's disease, showing significant slowing of disease progression. QURE's AMT-130 demonstrated robust clinical benefits, including improved daily activities, cognition, and motor function, despite small sample size and external control limitations. Financially, QURE is well-positioned with over $700 mi...
More uniQure N.V. News

Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Head office Netherlands
CEO Matt Kapusta
Employees 209
Founded 2012
Website www.uniqure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today